scispace - formally typeset
J

Jonathan Bennett

Researcher at Glenfield Hospital

Publications -  52
Citations -  3246

Jonathan Bennett is an academic researcher from Glenfield Hospital. The author has contributed to research in topics: Lung cancer & Thoracoscopy. The author has an hindex of 22, co-authored 47 publications receiving 2617 citations. Previous affiliations of Jonathan Bennett include University of Nottingham & British Thoracic Society.

Papers
More filters
Journal ArticleDOI

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Nicholas McGranahan, +219 more
- 30 Nov 2017 - 
TL;DR: It is found that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.
Journal ArticleDOI

The promise and peril of chemical probes.

Cheryl H. Arrowsmith, +53 more
TL;DR: A community-driven wiki resource to improve quality and convey current best practice on chemical probes, and to help address shortcomings of poor quality or that are used incorrectly generate misleading results.
Journal ArticleDOI

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Frederick Arce Vargas, +250 more
- 18 Apr 2017 - 
TL;DR: Use of an anti‐CD25 antibody with enhanced binding to activating Fc&ggr;Rs led to effective depletion of tumor‐infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors.
Journal ArticleDOI

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

TL;DR: TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape of lung cancer by tracking clonal heterogeneity and tumour evolution from diagnosis to relapse.
Journal ArticleDOI

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

TL;DR: Formoterol has a more rapid onset for most end points whereas salmeterol has slightly more prolonged activity, and both drugs have a relatively modest therapeutic window, which is similar to the fourfold difference in recommended doses.